Boston – A year ago, 58‑year‑old Molly Falco underwent a groundbreaking kidney transplant at Mass General Brigham, receiving an organ from a genetically engineered pig. The procedure, the fourth of its kind at the hospital, marks a significant step toward expanding treatment options for the thousands of Americans who rely on dialysis.
Patient perspective
“I just thought, ‘What a cool thing to help the future in medicine,'” Falco said, reflecting on her decision to become a pioneer in experimental transplantation. She added, “I got a transplant. I was really fortunate. And I’m still alive, and I don’t have to do dialysis.” Her gratitude underscores the personal impact of this medical advance.
Medical team’s view
Dr. Leo Riella, medical director of the kidney transplant program at Mass General Brigham, praised Falco and other volunteers for their willingness to take on the risks associated with novel procedures. “Our patients are the true heroes here,” he said. “They’re pioneers because they are putting themselves at risk to advance the science and create options for treatments that currently are not available for patients that are currently on dialysis.” He expressed optimism about the progress, noting that Falco’s successful year‑long outcome “gives us extreme hope that it is feasible to do these transplants.”
History of the program
The hospital performed the world’s first pig kidney transplant in 2024, when patient Rick Slayman survived 52 days before passing from an unrelated heart condition. In 2025, a second patient, Tim Andrews, received a pig kidney that functioned for 271 days before being replaced with a human donor organ. Falco, the fourth recipient, joins a small but growing cohort of patients helping researchers refine the technique.
Challenges and next steps
One of the primary challenges with pig kidney transplants is the need for intensified immunosuppressive medication to prevent organ rejection, which can raise infection risk. Dr. Riella explained that the team has been learning “little tricks” about which medications can be maintained and which doses can be reduced, aiming to balance efficacy with safety.
Looking ahead, a new clinical study slated for next year aims to provide further data on long‑term outcomes. “Hopefully, if the results are positive, within five years or so, we may have a product that could be approved for humans and could be an alternative to dialysis for a select number of patients,” Dr. Riella said.
Community of recipients
Since Falco’s transplant, two additional patients at Mass General Brigham have received pig kidneys, and all three have formed a supportive “pig kidney” group chat. The informal network allows recipients to share experiences, medication tips, and encouragement as they navigate post‑transplant life.
Implications for dialysis patients
Dialysis currently serves over 500,000 Americans, many of whom face a demanding treatment schedule and reduced quality of life. If pig kidney transplants can be refined and approved for broader use, they could provide a durable, living‑organ alternative, potentially reducing the national burden of dialysis.
While the procedure remains experimental, the success stories emerging from Mass General Brigham illustrate the promise of xenotransplantation research. Continued support from patients, clinicians, and researchers will be essential as the field moves toward possible regulatory approval and wider clinical application.
Original reporting: KOAT Albuquerque — read the source article.